The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience.
Shaheer A. Khan
No relevant relationships to disclose
Margaret Callahan
Research Funding - Bristol-Myers Squibb
Michael Andrew Postow
No relevant relationships to disclose
Paul B. Chapman
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose
Mark Andrew Dickson
No relevant relationships to disclose
Sandra P. D'Angelo
No relevant relationships to disclose
Jason John Luke
No relevant relationships to disclose
Mark J. Bluth
No relevant relationships to disclose
Ruth Ann Roman
No relevant relationships to disclose
Mary Montefusco
No relevant relationships to disclose
Christopher Andrew Barker
No relevant relationships to disclose
David H. Abramson
No relevant relationships to disclose
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Richard D. Carvajal
No relevant relationships to disclose